Dorota Lubgan
Overview
Explore the profile of Dorota Lubgan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
178
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Szwed M, Jost T, Majka E, Gharibkandi N, Majkowska-Pilip A, Frey B, et al.
Int J Mol Sci
. 2025 Feb;
26(4).
PMID: 40004038
Near-infrared light (NIR)-responsive metal-based nanoparticles (NPs) could be used for tumour therapy. We examined how platinum (Pt), gold (Au), and core-shell Pt-Au NPs affect the viability of human hepatocellular carcinoma...
2.
Poczta A, Krzeczynski P, Ionov M, Rogalska A, Gaipl U, Marczak A, et al.
Int J Mol Sci
. 2022 Nov;
23(22).
PMID: 36430734
Myeloablative therapy with highdoses of the cytostatic drug melphalan (MEL) in preparation for hematopoietic cell transplantation is the standard of care for multiple myeloma (MM) patients. Melphalan is a bifunctional...
3.
Karius A, Lotter M, Kreppner S, Schaller V, Lubgan D, Grigo J, et al.
Brachytherapy
. 2022 Jun;
21(5):635-646.
PMID: 35643593
Purpose: Seed brachytherapy is a well-established treatment modality for prostate cancer. However, there is still a lack of profound characterizations of seed motions within the prostate. We assessed these dynamics...
4.
Lubgan D, Semrau S, Lambrecht U, Gaipl U, Fietkau R
Strahlenther Onkol
. 2021 Jul;
198(2):110-122.
PMID: 34255094
Purpose: The aim of this study was to evaluate the safety and long-term tumor control after stereotactic radiotherapy (SRT) with 12 × 6 Gy of patients with primary bronchial carcinoma...
5.
Multhoff G, Seier S, Stangl S, Sievert W, Shevtsov M, Werner C, et al.
Clin Cancer Res
. 2020 Sep;
26(20):5368-5379.
PMID: 32873573
Purpose: Non-small cell lung cancer (NSCLC) is a fatal disease with poor prognosis. A membrane-bound form of Hsp70 (mHsp70) which is selectively expressed on high-risk tumors serves as a target...
6.
Fietkau R, Hecht M, Hofner B, Lubgan D, Iro H, Gefeller O, et al.
Radiother Oncol
. 2020 Feb;
144:209-217.
PMID: 32044419
Background And Purpose: This multicenter, phase 3 trial investigates whether the incorporation of concurrent paclitaxel and cisplatin together with a reduced total dose of radiotherapy is superior to standard fluorouracil-cisplatin...
7.
Rutzner S, Ganslandt T, Fietkau R, Prokosch H, Lubgan D
JCO Clin Cancer Inform
. 2019 Oct;
3:1-11.
PMID: 31599645
Purpose: Clinical data warehouses (cDWHs) and cancer registry databases have enabled researchers to conduct clinical analytics with structured electronic health record data. However, these secondary electronic health record sources are...
8.
Breheret M, Lubgan D, Haderlein M, Hecht M, Traxdorf M, Schmidt D, et al.
Eur Arch Otorhinolaryngol
. 2019 Oct;
277(1):245-254.
PMID: 31583430
Introduction: The response to induction chemotherapy (IC) predicts local control after conservative treatment of laryngeal, meso- and hypopharyngeal head and neck squamous cell carcinoma (HNSCC) and can thus help to...
9.
Koca S, Distel L, Lubgan D, Weissmann T, Lambrecht U, Lang-Welzenbach M, et al.
Strahlenther Onkol
. 2019 Mar;
195(8):745-755.
PMID: 30877350
Purpose: To prospectively evaluate the time course of pain response and toxicity after linear accelerator-based whole-nerve-encompassing radiosurgery (LINAC-SRS) using a uniform treatment schedule for dosing and target volume definition in...
10.
Semrau S, Lubgan D
Strahlenther Onkol
. 2019 Mar;
195(6):570-572.
PMID: 30847534
No abstract available.